Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Settle on Informed Conclusions about Senior Insuranc. - 2Phenomenal Web-based MBA Stages for Proficient Headway
- 3Miss Thailand Pageant Contestant's Veneers Fall Out During Speech on Stage
- 4Nexi expands alliance with PayPal
- 5Dominating Monetary Administration: A Bit by bit Manual for Making an Individual Financial plan
- Holden Commodore Turbo BT1 Police Interceptor Offered for Sale in Australia
- ‘It’s Israeli policy’: Report reveals abuse of Palestinians in prisons
- Hand Skin Is Additionally Significant - What You Ought to Realize About Hand Cream
- Explainer-What Novo Nordisk's weight-loss pill approval means for company, patients
- Satellite space quiz: What's orbiting Earth?
- Analysis-NASA's moon mission tests aerospace old guard as SpaceX, Blue Origin hover
- From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- Why Tourists May Want To Reconsider Traveling To This Popular Spot In Italy In 2026
- Flash flooding causes highways to close to and from Eilat
